Amylin and Calcitonin: Potential Therapeutic Strategies to Reduce Body Weight and Liver Fat

by David S. Mathiesen, Asger Lund, Tina Vilsbøll, Tina Vilsbøll, Tina Vilsbøll, Filip K. Knop, Filip K. Knop, Filip K. Knop, Filip K. Knop, Jonatan I. Bagger, Jonatan I. Bagger
Published 2021-01-01

Mechanisms of the incretin effect in subjects with normal glucose tolerance and patients with type 2 diabetes.

by Andrea Mari, Jonatan I Bagger, Ele Ferrannini, Jens J Holst, Filip K Knop, Tina Vilsbøll
Published 2013-01-01

The Effects of Dual GLP-1/GIP Receptor Agonism on Glucagon Secretion—A Review

by David S. Mathiesen, Jonatan I. Bagger, Natasha C. Bergmann, Asger Lund, Mikkel B. Christensen, Tina Vilsbøll, Filip K. Knop
Published 2019-08-01

Circulating Levels of the Soluble Receptor for AGE (sRAGE) during Escalating Oral Glucose Dosages and Corresponding Isoglycaemic i.v. Glucose Infusions in Individuals with and with...

by Amelia K. Fotheringham, Jonatan I. Bagger, Danielle J. Borg, Domenica A. McCarthy, Jens J. Holst, Tina Vilsbøll, Filip K. Knop, Josephine M. Forbes
Published 2020-09-01

No detectable effect of a type 2 diabetes-associated TCF7L2 genotype on the incretin effect

by David S Mathiesen, Jonatan I Bagger, Katrine B Hansen, Anders E Junker, Astrid Plamboeck, Signe Harring, Thomas Idorn, Mads Hornum, Jens J Holst, Anna E Jonsson, Torben Hansen, Tina Vilsbøll, Asger Lund, Filip K Knop
Published 2020-12-01

One Year’s Treatment with the Glucagon-Like Peptide 1 Receptor Agonist Liraglutide Decreases Hepatic Fat Content in Women with Nonalcoholic Fatty Liver Disease and Prior Gestationa...

by Louise Vedtofte, Emilie Bahne, Signe Foghsgaard, Jonatan I. Bagger, Camilla Andreasen, Charlotte Strandberg, Peter M. Gørtz, Jens J. Holst, Henning Grønbæk, Jens A. Svare, Tine D. Clausen, Elisabeth R. Mathiesen, Peter Damm, Lise L. Gluud, Filip K. Knop, Tina Vilsbøll
Published 2020-10-01